Kong Y - Search Results

1

Major response to everolimus in melanoma with acquired imatinib resistance.

Si L, Xu X, Kong Y, Flaherty KT, Chi Z, Cui C, Sheng X, Li S, Dai J, Yu W, Guo J. Si L, et al. Among authors: kong y. J Clin Oncol. 2012 Feb 1;30(4):e37-40. doi: 10.1200/JCO.2011.37.9644. Epub 2011 Dec 12. J Clin Oncol. 2012. PMID: 22162580 No abstract available.

2

[Insulin resistance and non-insulin dependent diabetes mellitus].

Kong YH, Chi ZS. Kong YH, et al. Zhonghua Nei Ke Za Zhi. 1992 Jan;31(1):42-5. Zhonghua Nei Ke Za Zhi. 1992. PMID: 1395912 Review. Chinese. No abstract available.

3

[Autologous regulatory T cells can suppress the proliferation of lymphoma cell line in vitro].

Ying ZT, Guo J, Ren J, Kong Y, Yuan ZH, Liu XJ, Zhang C, Zheng W, Song YQ, Zhang YT, Zhu J. Ying ZT, et al. Among authors: kong y. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Jun;17(3):583-7. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009. PMID: 19549368 Chinese.

4

[Regulatory T cells inhibit proliferation of mouse lymphoma cell line EL4 in vitro].

Zhang C, Kong Y, Guo J, Ying ZT, Yuan ZH, Zhang YT, Zheng W, Song YQ, Li PP, Zhu J. Zhang C, et al. Among authors: kong y. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Oct;18(5):1198-203. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010. PMID: 21129260 Chinese.

5

Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.

Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, Chi Z, Li S, Mao L, Guo J. Si L, et al. Among authors: kong y. Eur J Cancer. 2012 Jan;48(1):94-100. doi: 10.1016/j.ejca.2011.06.056. Epub 2011 Jul 23. Eur J Cancer. 2012. PMID: 21788131

6

A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.

Cui C, Mao L, Chi Z, Si L, Sheng X, Kong Y, Li S, Lian B, Gu K, Tao M, Song X, Lin T, Ren X, Qin S, Guo J. Cui C, et al. Among authors: kong y. Mol Ther. 2013 Jul;21(7):1456-63. doi: 10.1038/mt.2013.79. Epub 2013 May 14. Mol Ther. 2013. PMID: 23670576 Free PMC article. Clinical Trial.

7

Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.

Lian B, Si L, Cui C, Chi Z, Sheng X, Mao L, Li S, Kong Y, Tang B, Guo J. Lian B, et al. Among authors: kong y. Clin Cancer Res. 2013 Aug 15;19(16):4488-98. doi: 10.1158/1078-0432.CCR-13-0739. Epub 2013 Jul 5. Clin Cancer Res. 2013. PMID: 23833309 Clinical Trial.

8

Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.

Dai J, Kong Y, Si L, Chi Z, Cui C, Sheng X, Mao L, Li S, Lian B, Yang R, Liu S, Xu X, Guo J. Dai J, et al. Among authors: kong y. Clin Cancer Res. 2013 Dec 15;19(24):6935-42. doi: 10.1158/1078-0432.CCR-13-1266. Epub 2013 Oct 16. Clin Cancer Res. 2013. PMID: 24132921

9

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.

Li S, Kong Y, Si L, Chi Z, Cui C, Sheng X, Guo J. Li S, et al. Among authors: kong y. BMC Cancer. 2014 May 28;14:376. doi: 10.1186/1471-2407-14-376. BMC Cancer. 2014. PMID: 24886512 Free PMC article.

10

[Genetic polymorphisms of PDGFR associated with thrombocytopenia in Chinese patients with clear-cell metastatic renal cell carcinoma treated with sunitinib].

Sheng X, Kong Y, Tang H, Lian B, Mao L, Chi Z, Cui C, Si L, Wang X, Yan X, Li S, Dai J, Guo J. Sheng X, et al. Among authors: kong y. Zhonghua Yi Xue Za Zhi. 2014 Oct 21;94(38):2988-91. Zhonghua Yi Xue Za Zhi. 2014. PMID: 25547700 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,958 results

Search Page

Filters